Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Frenzel

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Nature Communications|February 22, 2018
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemiaCarmen D Herling, Nima Abedpour, Jonathan Weiss, et al.
Leukemia|November 7, 2019
ATM activity in T cells is critical for immune surveillance of lymphoma in vivoArina Riabinska, Daria Lehrmann, Ron Daniel Jachimowicz, et al.
Blood|February 4, 2021
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1Vivien Kohlhaas, Stuart James Blakemore, Mona Al-Maarri, et al.
Immunity|September 3, 2024
Antibodies and complement are key drivers of thrombosisKonstantin Stark, Badr Kilani, Sven Stockhausen, et al.
Blood|April 7, 2016
B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in miceGero Knittel, Paul Liedgens, Darya Korovkina, et al.
Blood|June 15, 2022
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignanciesD Thomalla, L Beckmann, C Grimm, et al.
Blood Cancer Discovery|January 15, 2021
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular VulnerabilitiesRuth Flümann, Tim Rehkämper, Pascal Nieper, et al.
Annals of Hematology|July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLLydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Nature Communications|February 22, 2018
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemiaCarmen D Herling, Nima Abedpour, Jonathan Weiss, et al.
Leukemia|November 7, 2019
ATM activity in T cells is critical for immune surveillance of lymphoma in vivoArina Riabinska, Daria Lehrmann, Ron Daniel Jachimowicz, et al.
Blood|February 4, 2021
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1Vivien Kohlhaas, Stuart James Blakemore, Mona Al-Maarri, et al.
Immunity|September 3, 2024
Antibodies and complement are key drivers of thrombosisKonstantin Stark, Badr Kilani, Sven Stockhausen, et al.
Blood|April 7, 2016
B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in miceGero Knittel, Paul Liedgens, Darya Korovkina, et al.
Blood|June 15, 2022
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignanciesD Thomalla, L Beckmann, C Grimm, et al.
Blood Cancer Discovery|January 15, 2021
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular VulnerabilitiesRuth Flümann, Tim Rehkämper, Pascal Nieper, et al.
Annals of Hematology|July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLLydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.
Pageof 5